Skip to main content

Genaissance and Otsuka Pharmaceutical to Collaborate on PGx Study of Drug Response

NEW YORK, Sept. 21 (GenomeWeb News) - Genaissance Pharmaceuticals will conduct genotyping studies for Otsuka Pharmaceutical of Japan, the companies said today.

 

Under the research collaboration, New Haven, Conn.-based Genaissance will apply its HAP technology to identify genetic markers related to drug response. Both companies will own intellectual property resulting from the collaboration and will be eligible for royalties on revenues from diagnostic products that come out of the project.

 

The Otsuka Pharmaeutical Group, based in Tokyo, comprises 73 companies with 23,000 employees and has $4.4 billion in annual revenues.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.